Nanopublications

Matches in Nanopublications for { ?s ?p ?o <http://www.tkuhn.ch/bel2nanopub/RAtHU0J_ULtG30BeC-TUs8p52IPZFKy6RVcTnaUJAbI_U#provenance>. }

Showing items 1 to 14 of 14 with 100 items per page.

_6 label "Selventa" provenance.
large_corpus.bel title "BEL Framework Large Corpus Document" provenance.
_4 title "Chemical Society Reviews 1998 volume 27" provenance.
_4 type "Other" provenance.
_4 identifier "Chemical Society Reviews 1998 volume 27" provenance.
large_corpus.bel description "Approximately 61,000 statements." provenance.
large_corpus.bel version "1.4" provenance.
large_corpus.bel authoredBy _6 provenance.
assertion wasDerivedFrom large_corpus.bel provenance.
assertion wasDerivedFrom _5 provenance.
assertion hadPrimarySource _4 provenance.
_5 wasQuotedFrom _4 provenance.
_5 value "A pure oestrogen receptor antagonist, ICI182780 11, was subsequently discovered and is now in late-stage clinical trial. 4.3 LHRH agonists Luteinizing hormone releasing hormone (LHRH) agonists form a third class of hormonal therapy for breast cancer, albeit only in pre-menopausal women. This limitation arises from their inhibitory effect on luteinizing hormone (LH) release from the pituitary (see Fig. 4) and consequent suppression of ovarian stimulation for oestrogen production. Whilst there are LHRH antagonists in clinical study, the ability of the agonists to mimic successfully the natural inhibitory feedback effect of oestrogen at the pituitary by inducing LHRH receptor downregulation provides a rare superiority over direct blockade. The agonists are all close analogues of LHRH 15, but their potency has had to be even greater than that of the natural decapeptide hormone itself to achieve the downregulating effect.15" provenance.